Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/CollPlant Biotechnologies Ltd/ 6-K

SEC Filing · 6-K

CollPlant Biotechnologies Ltd

CLGNNASDAQEQUITYCurrent

SEC Filing

Filed Sep 22, 2026Accepted Sep 22, 2026, 10:40 AM EDTCIK 1631487Accession 0001213900-26-102033
View company →Permanent SEC source ↗
Share

Company context

We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology. These products address indications for the diverse fields of tissue repair and aesthetics, and are ushering in a new era in regenerative and aesthetic medicine.

Current securities

CLGNNASDAQ · EQUITY · Current

Recent company filings

  1. 6-K filingSep 18, 2026
  2. 4 filingSep 8, 2026
  3. 6-K filingSep 4, 2026
  4. 6-K filingSep 3, 2026
  5. 6-K filingSep 1, 2026

As-filed source

Primary evidence
As filedOpen full document ↗